================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 10, 2001
TANOX, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-30231 76-0196733
(State or other jurisdiction (Commission File No.) (I.R.S. Employer
of incorporation) Identification No.)
10301 STELLA LINK, SUITE 110, HOUSTON, TEXAS 77025-5497
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: 713-578-4000
================================================================================
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
Genentech, Inc. and Novartis AG today issued a statement regarding their receipt
of a Complete Response letter for Xolair(TM) (Omalizumab) from the U.S. Food and
Drug Administration. Tanox's press release and excerpts from the joint press
release of Genentech and Novartis are attached as Exhibits hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99.1 -- Press Release of Tanox Inc. issued on July 10, 2001.
99.2 -- Excerpts from the Joint Press Release of Genentech, Inc. and
Novartis AG issued on July 10, 2001.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: July 10, 2001 TANOX, INC.
By: /s/ Michael A. Kelly
-------------------------------------
Michael A. Kelly
Vice President of Finance and CFO
3